Monocyte-mediated rotenone neurotoxicity towards human neuroblastoma SH-SY5Y: Role of mitogen-activated protein kinases

Biological and Pharmaceutical Bulletin

Volumn 29, Issue 7, 2006, Pages 1372-1377

  Zhao, Fei Li ^a   Hu, Jing Hui ^a   Zhu, Xing Zu ^a  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

Apoptosis; Mitogen activated protein kinase (MAPK); Monocyte; Neuroblastoma; Rotenone

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUMBROMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BROMINE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; ROTENONE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL DEATH; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INCUBATION TIME; MONOCYTE; NEUROBLASTOMA; NEUROTOXICITY; SUPERNATANT;

APOPTOSIS; CELL COMMUNICATION; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME INHIBITORS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; MONOCYTES; NEUROBLASTOMA; ROTENONE;

EID: 33745685732     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.29.1372     Document Type: Article

References (30)

1. Kweon G. R., Marks J. D., Krencik R., Leung E. H., Schumacker P. T., Hyland K., Kang U. J., J. Biol. Chem., 279, 51783-51792 (2004).
2. Jenner P., Trends Neurosci., 24, 245-247 (2001).
3. Gao H. M., Hong J. S., Zhang W., Liu B., J. Neurosci., 22, 782-790 (2002).
4. Gao H. M., Liu B., Hong J. S., J. Neurosci., 23, 6181-6187 (2003).
5. Sherer T. B., Betarbet R., Kim J. H., Greenamyre J. T., Neurosci. Lett., 341, 87-90 (2003).
6. Langston J. W., Forno L. S., Tetrud J., Reeves A. G., Kaplan J. A., Karluk D., Ann. Neurol., 46, 598-605 (1999).
7. McGeer P. L., Itagaki S., Boyes B. E., McGeer E. G., Neurology, 38, 1285-1291 (1988).
8. Herrera A. J., Castano A., Venero J. L., Cano J., Machado A., Neurobiol. Dis., 7, 429-447 (2000).
9. Kim W. G., Mohney R. P., Wilson B., Jeohn G. H., Liu B., Hong J. S., J. Neurosci., 20, 6309-6316 (2000).
10. Wu D. C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D. K., Ischiropoulos H., Przedborski S., J. Neurosci., 22, 1763-1771 (2002).
11. Zoccarato F., Toscano P., Alexandre A., J. Biol. Chem., 280, 15587-15594 (2005).
12. Liu B., Hong J. S., J. Pharmacol. Exp. Ther., 304, 1-7 (2003).
13. Merrill J. E., Benveniste E. N., Trends Neurosci., 19, 331-333 (1996).
14. Chao C. C., Hu S., Molitor T. W., Shaskan E. G., Peterson P. K., J. Immunol., 149, 2736-2741 (1992).
15. Lander H. M., FASEB J., 11, 118-124 (1997).
16. Droge W., Physiol. Rev., 82, 47-95 (2002).
17. Pawate S., Shen Q., Fan F., Bhat N. R., J. Neurosci. Res., 77, 540-551 (2004).
18. Klegeris A., Walker D. G., McGeer P. L., Neuropharmacology, 38, 1017-1025 (1999).
19. Giri R. K., Selvaraj S. K., Kalra V. K., J. Immunol., 170, 5281-5294 (2003).
20. Wang L. Z., Sun W. C., Zhu X. Z., Eur. J. Pharmacol., 508, 57-68 (2005).
21. Nakatani N., Ichimaru M., Moriyasu M., Kato A., Biol. Pharm. Bull., 28, 83-86 (2005).
22. Liu H. Q., Zhu X. Z., Weng E. Q., Acta Pharmacologica Sin., 26, 17-26 (2005).
23. Chan A. S., Yip E. C., Yung L. Y., Pang H., Luk S. C., Pang S. F., Wong Y. H., Biol. Pharm. Bull., 28, 1645-1650 (2005).
24. Romagnoli P., Bron C., J. Immunol., 158, 5757-5764 (1997).
25. Biedler J. L., Roffler-Tarlov S., Schachner M., Freedman L. S., Cancer Res., 38, 3751-3757 (1978).
26. Wang X., Qin Z. H., Leng Y., Wang Y., Jin X., Chase T. N., Bennett M. C., J. Neurochem., 83, 1094-1102 (2002).
27. Bhat N. R., Zhang P., J. Neurochem., 72, 112-119 (1999).
28. Salsman S., Felts N., Pye Q. N., Floyd R. A., Hensley K., Arch. Biochem. Biophys., 386, 275-280 (2001).
29. Lee J., Chan S. L., Mattson M. P., Neuromolecular Med., 2, 29-45 (2002).
30. Park S. Y., Lee H., Hur J., Kim S. Y., Kim H., Park J. H., Cha S., Kang S. S., Cho G. J., Choi W. S., Suk K., Brain Res. Mol. Brain Res., 107, 9-16 (2002).